Intellia Therapeutics Head office building

Investors
& Media

Banner Menu

Press Releases

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read More

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Read More

Upcoming
Events

More events are coming soon.

Stock Information

Minimum 15 minutes delayed. Source: LSEG